IBM's Role and Relevance in the Pharmaceutical Industry (U.S. Focus)

By IntuitionLabs • 4/18/2025 • 35 min read

ibm pharmaceutical drug-discovery artificial-intelligence cloud-computing hybrid-cloud quantum-computing regulatory-compliance data-security blockchain watson watsonx red-hat case-studies

IBM’s Role and Relevance in the Pharmaceutical Industry (U.S. Focus)

Introduction

IBM has a long-standing presence in the pharmaceutical sector, evolving from providing enterprise IT infrastructure to driving cutting-edge innovations in cloud computing and artificial intelligence (AI). In the United States, many pharma and biotech companies rely on IBM’s technology and services for research and development (R&D), data management, regulatory compliance, and secure IT operations. This report provides an in-depth look at IBM’s current relevance in pharma – from AI-powered drug discovery and hybrid cloud infrastructure to compliance support – and how IBM positions itself against major competitors like Amazon Web Services (AWS), Microsoft Azure, and Google Cloud in this highly regulated industry. The goal is to inform IT professionals in pharma about IBM’s contributions, partnerships, and real-world case studies shaping the industry today.

AI and Drug Discovery: From IBM Watson to Generative Models

One of IBM’s most significant contributions to pharmaceutical R&D has been in applying AI and machine learning to accelerate drug discovery. **IBM Watson** – the AI platform famous for natural language understanding – was initially applied to life sciences with great ambitions. For example, IBM launched *Watson for Drug Discovery* in the mid-2010s, a tool meant to sift through massive biomedical data to find novel drug targets and insights. In a collaboration with Pfizer starting in 2016, Watson for Drug Discovery was used to help Pfizer’s immuno-oncology researchers analyze disparate data sources and identify new hypotheses in cancer drug research (Report: IBM is ending sales of Watson for Drug Discovery - MedCity News). Early successes of IBM’s AI included work with Baylor College of Medicine, where a Watson-driven system analyzed **23 million** medical abstracts and identified *six* new proteins that regulate the tumor suppressor p53 – discoveries that might have taken scientists years to find manually (IBM Watson’s Startling Cancer Coup - TIME) (IBM Watson’s Startling Cancer Coup - TIME). This demonstrated how cognitive computing could dramatically speed up uncovering disease targets, effectively finding in **months** what previously took decades of research (IBM Watson’s Startling Cancer Coup - TIME).

Despite these promising examples, IBM faced challenges in turning Watson’s AI into a scalable product for pharma R&D. By 2019, IBM ceased selling Watson for Drug Discovery, as it “wasn’t

yielding large enough financial returns" and had sluggish uptake in the market (Report: IBM is ending sales of Watson for Drug Discovery - MedCity News). (IBM continued to support existing users like Pfizer's research team, but the offering was refocused (Report: IBM is ending sales of Watson for Drug Discovery - MedCity News).) This pivot led IBM to rethink its strategy in healthcare AI. Rather than a one-size platform for drug discovery, IBM began targeting more specific AI applications and collaborations.

Today, IBM's pharmaceutical AI efforts are resurging through **generative AI and foundation models**. In 2023, IBM introduced **watsonx**, a platform for building and deploying large-scale AI models (including domain-specific models). A recent high-profile example is IBM's partnership with German drugmaker **Boehringer Ingelheim** to apply **generative AI** in antibody discovery. Announced in late 2023, this collaboration allows Boehringer to leverage an IBM-developed foundation model trained on vast biological data to **generate and optimize therapeutic antibodies in silico** (Boehringer to use IBM's foundation model for antibody discovery) (Boehringer to use IBM's foundation model for antibody discovery). The generative model can propose novel antibody structures for a given disease target, which researchers then refine and test experimentally. Boehringer's global head of biotherapeutics discovery noted that *"by joining forces with IBM scientists we will develop an unprecedented platform for accelerated antibody discovery"*, underscoring the hope that AI can **expedite what is traditionally a time-consuming R&D process** (Boehringer to use IBM's foundation model for antibody discovery). This move into generative AI indicates IBM's current relevance in pharma R&D: rather than selling a standalone product, IBM is co-creating AI solutions with pharma partners to tackle specific challenges like biologics design. Another example is **Moderna's** partnership with IBM to explore how **AI models** might assist in mRNA vaccine and therapy development. In 2023 Moderna began working with IBM's AI researchers to utilize *MoLFormer* (an IBM-designed model for molecular property prediction) to help design better lipid nanoparticles for delivering mRNA drugs (Moderna enlists IBM for quantum computing, AI training - Fierce Biotech). These AI tools aim to optimize drug delivery components at a molecular level, potentially improving efficacy and stability of mRNA vaccines.

In addition to drug *design*, IBM's AI is also supporting clinical development and analysis of real-world health data. (IBM had invested in health data analytics through its Watson Health unit, which compiled clinical and outcomes data, though that division was divested in 2022.) Even after that change, IBM's research teams continue to apply AI in domains like **biomarker discovery**, **drug repurposing**, and personalized medicine. For instance, IBM is collaborating with the **Michael J. Fox Foundation** using AI to sift through patient data and identify patterns in Parkinson's disease subtypes (Moderna enlists IBM for quantum computing, AI training - Fierce Biotech). These initiatives align with pharma's needs to find the right targets and patient segments for new therapies. Overall, IBM remains a significant player in pharma R&D by providing advanced AI capabilities – from natural language processing that can read scientific literature, to deep learning models that generate drug candidates – often through partnerships that combine IBM's technology with a pharma company's data and expertise.

Cloud Computing and Data Infrastructure in Pharma

Pharmaceutical companies, especially large ones in the U.S., have historically relied on IBM for robust computing infrastructure. IBM continues to serve this role today through its **hybrid cloud and data platforms**. Many pharma firms run critical enterprise systems on IBM hardware or cloud services to ensure high performance and reliability. For example, **Pfizer** – one of the world's largest pharma companies – chose IBM Power Systems as the backbone for its global SAP ERP environment, which includes vital applications like drug **track-and-trace** (serialization for supply chain) and financials. Pfizer found IBM's Power servers could handle its single, unified ERP with better scalability and reliability than a distributed x86 cloud approach (Pfizer - IBM) (Pfizer - IBM). By consolidating on IBM infrastructure, Pfizer achieved a more efficient, "single source of truth" for operations and reporting, and even as they upgraded to SAP S/4HANA, they retained IBM Power for its ability to **scale-up** and run extremely large workloads (Pfizer's core database shrank from 75 TB to 5.5 TB on the new system) (Pfizer - IBM) (Pfizer - IBM). This case illustrates IBM's ongoing relevance as a provider of mission-critical IT in pharma – especially in scenarios where performance, reliability, and on-premises control are paramount.

Beyond on-premises hardware, **IBM Cloud** is also utilized in the life sciences sector, albeit at a smaller scale compared to hyperscalers. IBM's strategy in cloud for pharma emphasizes **hybrid deployments** – enabling companies to run some workloads in IBM's public cloud data centers while seamlessly linking to on-site systems. The centerpiece is **Red Hat OpenShift** (IBM acquired Red Hat in 2019), which many pharma IT teams use to containerize applications and move them between on-prem and cloud environments. IBM's cloud offerings are designed with the stringent regulatory requirements of healthcare and pharma in mind. For instance, IBM Cloud has dedicated frameworks for **GxP compliance**, adhering to Good Practice guidelines (like GMP, GCP, GLP) that govern drug manufacturing, clinical trials, and labs (IBM Cloud GXP compliance - IBM) (IBM Cloud GXP compliance - IBM). IBM maintains certifications such as **ISO 9001 and 27001** for its cloud data centers and services, and provides quality management systems to help pharma clients validate that their cloud-hosted systems meet FDA requirements (IBM Cloud GXP compliance - IBM). This means pharma companies can leverage cloud scalability while remaining compliant with regulations like FDA 21 CFR Part 11 (which covers electronic records/signatures) – a balance not all cloud providers can deliver as easily. IBM highlights that its cloud environment is highly secured and controlled, offering documented procedures for everything from user access to change management, which is crucial in validated pharma systems (IBM Cloud GXP compliance - IBM).

High-performance computing (HPC) is another area where IBM's infrastructure has supported pharmaceutical research. IBM has been a leader in supercomputing – notably, it built the **"Summit"** supercomputer (formerly the world's fastest) which was used extensively in drug discovery simulations. During the COVID-19 pandemic in 2020, IBM took a lead role in the **COVID-19 High-Performance Computing Consortium**, a public-private initiative launched with the White House to provide researchers worldwide with free access to supercomputers for COVID research (COVID-19 HPC Consortium one year on: Getting ready for the next crisis - IBM

Research). IBM contributed its computing resources and coordination, enabling scientists to model virus proteins and screen billions of molecules for potential treatments in a matter of days. The results were significant – researchers "found new molecules and proteins able to fight the coronavirus" and achieved insights into how the virus's mutations affect vaccines and therapies (COVID-19 HPC Consortium one year on: Getting ready for the next crisis - IBM Research). This demonstrated IBM's capacity to marshal computing power for urgent pharmaceutical research at a national (even global) scale. It also showcased IBM's collaborative approach: bringing together competitors and academics under a unified cause, leveraging IBM's research expertise in fields like computational chemistry.

IBM is also looking ahead by investing in **quantum computing** for drug discovery and molecular modeling. Quantum computers have the potential to solve complex biochemical calculations far faster than classical computers. Recognizing this, IBM formed a landmark 10-year partnership with **Cleveland Clinic** (a major U.S. medical research center) to establish the **Discovery Accelerator** – a joint center with an on-premises **IBM Quantum System One** dedicated to healthcare research (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One) (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One). This is the **first quantum computer in the world deployed on-site for biomedical and life sciences R&D**, reflecting IBM's commitment to push the boundaries of pharma research technology. Researchers at Cleveland Clinic are using IBM's quantum and AI tools to, for example, develop new methods for screening and optimizing drug molecules against specific protein targets (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One). Traditional computers struggle with the combinatorial complexity of molecule simulation, but quantum algorithms could evaluate interactions at a speed unattainable before. By 2023, IBM and Cleveland Clinic have begun projects that apply quantum computing to discover **novel therapeutics** and to search large drug databases for candidates that might treat diseases like Alzheimer's (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One). This initiative also uses IBM's **Generative Modeling** tools and the **IBM RXN** platform (which combines AI and robotics for automated chemistry) to accelerate compound design (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One) (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One). In parallel, IBM is working with pharma companies like **Moderna** on quantum computing: Moderna is part of IBM's Quantum Accelerator program, exploring quantum simulations to solve "tricky molecular-modeling problems" for next-generation mRNA vaccines (Moderna enlists IBM for quantum computing, AI training - Fierce Biotech). By investing in HPC and now quantum, IBM aims to provide pharma researchers with **state-of-the-art computational platforms** – whether via cloud-based access or on-premises systems – to speed up scientific discovery.

(Cleveland Clinic and IBM Begin Installation of IBM Quantum System One) *IBM and Cleveland Clinic launched the Discovery Accelerator, installing the first private-sector IBM Quantum System One on Cleveland Clinic's campus to pioneer uses of quantum computing and AI for drug discovery and biomedical research (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One) (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One).*

Researchers are experimenting with quantum algorithms to screen drug molecules for diseases and using AI tools to generate hypotheses and analyze vast biomedical data.

Compliance, Security, and Regulatory Support

Pharmaceutical companies operate in one of the most heavily regulated environments, and IBM leverages its enterprise IT strengths to support compliance, regulatory processes, and data security for these clients. One key aspect is **data security and privacy**. IBM has distinguished itself by offering advanced security features in its cloud and infrastructure products that align well with pharma's needs to protect sensitive research data and patient information. For example, IBM Cloud is known for its *"confidential computing"* capabilities and encryption. It is the **only major cloud provider** that uses FIPS 140-2 Level 4 certified hardware security modules, enabling a **"Keep Your Own Key" (KYOK)** encryption model (Best HIPAA-Compliant Cloud Storage in 2025). This means that a pharma company using IBM Cloud can retain sole control of encryption keys for its data – even IBM cannot access the decrypted data without the client's permission. Such a feature is highly valuable when dealing with confidential drug formulas, clinical trial data, or patient health records. IBM also supports **Bring Your Own Key (BYOK)** and other encryption standards, ensuring data is secure both at rest and in transit (Healthcare in the Cloud: Transforming Patient Care and Data ...) (Best HIPAA-Compliant Cloud Storage in 2025). In practical terms, these security options help pharmaceutical firms meet regulations like HIPAA (for patient data) and GDPR (for patient data privacy in clinical trials) by adding layers of protection.

IBM also provides software and services focused on **governance, risk management, and compliance (GRC)** specific to regulated industries. *IBM OpenPages*, an AI-driven GRC platform, is used across sectors including life sciences to track regulatory obligations and manage compliance workflows in a unified system (IBM OpenPages) (IBM OpenPages). For a pharma company, OpenPages can be configured to monitor compliance with FDA regulations, manage internal audits, and ensure quality controls (e.g., following Good Manufacturing Practices). Similarly, IBM's **Engineering Lifecycle Management** tools (formerly IBM Rational) help in managing documentation and verification for regulatory submissions, such as FDA filings for new drugs or devices. These tools ensure traceability from requirements to testing – crucial for FDA compliance – and can automate generation of required reports and validation evidence.

Another area IBM has supported is **regulatory compliance in pharma supply chains**. Counterfeit and diverted drugs are a major concern, and the U.S. **Drug Supply Chain Security Act (DSCSA)** mandates an interoperable system to trace prescription drugs. IBM has been at the forefront of blockchain solutions to ensure drug integrity. In 2019, IBM joined forces with KPMG, Merck, and Walmart in an FDA pilot program to test using **blockchain** to track and trace pharmaceuticals (IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity - Merck.com) (IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of

blockchain to protect pharmaceutical product integrity - Merck.com). The project created a shared, permissioned blockchain network that allowed real-time monitoring of drug shipments, aiming to **reduce the time to track a given medicine from days to seconds**. This blockchain system improved data accuracy among stakeholders and could even verify product conditions (like temperature) throughout the supply chain (IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity - Merck.com). As IBM's blockchain lead for healthcare noted, *"Blockchain has the potential to transform how pharmaceutical data is controlled, managed, shared and acted upon throughout the drug's lifetime"*, by providing an immutable audit trail of every transaction (IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity - Merck.com). The successful pilot demonstrated that blockchain could meet DSCSA requirements (IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity - Merck.com), and IBM's experience in other traceability projects (like IBM Food Trust for food safety) translated well to pharma. This kind of compliance support is critical as the DSCSA's 2023 full implementation deadline has arrived – IBM is well positioned with a proven solution that pharma companies and regulators could adopt to ensure every drug dispensed in the U.S. is legitimate and traceable.

In terms of supporting **regulatory processes**, IBM's consulting teams often assist pharma clients and health agencies in modernizing how they handle compliance. A notable example is IBM's work with the **National Association of Boards of Pharmacy (NABP)** (the U.S. body that supports state pharmacy regulators). IBM helped build a secure digital platform for NABP to manage data and credentials in an easily integrable, user-friendly way (Life sciences industry solutions - IBM). While not a drug manufacturer, NABP plays a role in pharmacy compliance, and IBM's solution improved their ability to ensure pharmacies and distributors meet standards. Likewise, IBM has worked with the FDA in applying AI to regulatory review processes – for instance, experimenting with AI to sift through adverse event reports or to analyze the huge volume of scientific submissions in new drug applications. IBM's proven natural language processing can potentially help regulators identify safety signals faster or cross-reference submissions with scientific literature, thereby indirectly speeding up approvals while maintaining rigor.

Finally, **cybersecurity** is a top priority in pharma, as evidenced by costly data breaches and intellectual property theft incidents in recent years. IBM, with its IBM Security division, provides end-to-end security solutions that many pharma companies use. IBM's **Guardium** data protection software, for instance, is used to monitor databases containing sensitive research or patient data – it can automatically flag unauthorized access or unusual data queries, helping companies prevent data leaks (Life sciences industry solutions - IBM). IBM also offers incident response services; given the rise of ransomware (even targeting labs and hospitals), pharma firms often have IBM on retainer to handle cyber incidents swiftly. The **Cost of a Data Breach Report** (by IBM Security) consistently shows healthcare (including pharma) has the highest breach costs of any industry, which reinforces the value of investing in AI-driven security and

automation to detect threats (Life sciences industry solutions - IBM). IBM's emphasis on trust and transparency (a theme it highlights in its corporate responsibility) resonates with pharma CIOs who must assure regulators and the public that critical systems – from clinical trial databases to manufacturing control systems – are secure.

Collaborations and Case Studies in Pharma

IBM's relevance in the pharma industry is perhaps best illustrated through its numerous **collaborations with leading pharmaceutical companies, research institutions, and government agencies**. These partnerships often pair IBM's technology with domain expertise from the partner, yielding innovative results and real-world impact. We've already touched on several such cases (Pfizer, Boehringer Ingelheim, Moderna, Cleveland Clinic). Here we'll highlight a few more diverse examples:

- **Moderna's Quantum and AI Initiative:** Moderna, based in Massachusetts, gained fame for its COVID-19 mRNA vaccine – and it continues to innovate aggressively. In April 2023, Moderna announced it is teaming up with IBM to explore **quantum computing and generative AI** for mRNA science (Moderna enlists IBM for quantum computing, AI training - Fierce Biotech) (Moderna enlists IBM for quantum computing, AI training - Fierce Biotech). As part of this partnership, Moderna's scientists are working with IBM's **Quantum Accelerator** program (informally for "quantum curious" companies) to train their team on quantum algorithms applicable to drug design (Moderna enlists IBM for quantum computing, AI training - Fierce Biotech). The goal is to prepare a "quantum-ready" workforce that can harness IBM's quantum systems to solve problems like modeling complex RNA folding or interactions that classical computers struggle with. Simultaneously, IBM is providing access to its generative AI models to help Moderna design new therapies – one concrete aim is using AI to optimize the **lipid nanoparticle** carriers for mRNA drugs, potentially improving how these medicines are delivered in the body (Moderna enlists IBM for quantum computing, AI training - Fierce Biotech). This collaboration is a strong validation of IBM's offerings: a cutting-edge biotech entrusting IBM to help integrate **next-gen tech (quantum + AI)** into its R&D pipeline.

- **Boehringer Ingelheim's AI-Driven Antibody Discovery:** Boehringer Ingelheim (BI) is a top-20 pharma company, and in 2023 it turned to IBM to accelerate discovery of **therapeutic antibodies**. Under a new agreement, BI is using IBM's AI **foundation model** – a large model pre-trained on biochemical data – to generate novel antibody candidates in silico (Boehringer to use IBM's foundation model for antibody discovery). The approach involves *in-silico* (computer-simulated) design of antibody sequences that could bind disease targets of interest, using generative algorithms to propose molecular structures that meet certain success criteria (Boehringer to use IBM's foundation model for antibody discovery). Those virtual antibodies are then synthesized and tested by BI's labs, and the experimental results are fed back to refine the AI model (Boehringer to use IBM's foundation model for antibody discovery). This closed-loop learning could significantly cut down the time to find a promising antibody therapy. Both companies see this as pioneering work – BI's research leader said the goal is an "unprecedented platform for accelerated antibody discovery" merging BI's pharma know-how with IBM's AI expertise (Boehringer to use IBM's foundation model for antibody discovery). It's a case where IBM isn't just a vendor but a true R&D partner, advancing the state of the art in biologics discovery.

- **Cleveland Clinic – Discovery Accelerator:** IBM's partnership with Cleveland Clinic is noteworthy not only for the technology (quantum computing as discussed earlier) but also as a model of industry-academic collaboration. The **Discovery Accelerator** launched in 2021 is a **10-year alliance** where IBM and Cleveland Clinic scientists work side by side on projects. Already, they have multiple projects underway that leverage IBM's tech: using **AI to scan genome sequencing data and drug databases to find existing drugs that might be repurposed** for diseases like Alzheimer's (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One), and improving AI models for predicting health outcomes (e.g., cardiovascular risk after surgery) by training on big clinical data sets (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One) (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One). Importantly, this collaboration is also training the next generation workforce – from internships to professional courses in data science, AI, and quantum – acknowledging that the **human expertise** is as crucial as the tech (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One). For IBM, this ensures a pipeline of talent skilled in their systems; for the healthcare sector, it builds capabilities that will last beyond the partnership.

- **FDA and CDC Engagements:** IBM has also engaged with U.S. government health agencies on various initiatives. We saw IBM's involvement in the FDA's blockchain pilot for DSCSA compliance. Another example is IBM's work with the **Department of Veterans Affairs (VA)**. In a program linked to the Cancer Moonshot initiative, IBM Watson for Genomics was used to help the VA interpret the genetic data of veterans' tumors to guide cancer treatment (How IBM's Watson Supercomputer Is Going to Help 10000 Veterans). By analyzing mutations and suggesting relevant precision therapies, Watson aimed to support oncologists in the VA's vast healthcare system. This public-private partnership (originally announced in 2016) allowed IBM to contribute its AI at scale – the goal was to help **10,000 veterans with cancer** by providing AI-driven insights into their disease (How the VA is Using AI to Target Cancer - The Atlantic). While Watson for Genomics and Oncology had mixed outcomes in the market, in the VA context it provided valuable lessons and a template for how AI could assist in evidence-based clinical decision support. IBM has also worked with the **Centers for Disease Control and Prevention (CDC)**, for instance in applying analytics to public health data (such as surveillance of prescription drug abuse, though details are often internal). These collaborations with government not only show IBM's commitment to public health and regulatory science, but they also deepen IBM's understanding of the broader **health ecosystem** that pharma operates in (from clinical care to population health).

- **Other Pharma IT Transformations:** IBM's consulting arm (IBM Consulting) regularly partners with pharma companies on digital transformation projects beyond R&D. For example, Indonesia's PT. **Holi Pharma** (a generic drug manufacturer) enlisted IBM to modernize its ERP and supply chain systems with SAP S/4HANA, resulting in more efficient operations and better growth capacity (Holi Pharma Digitally Transforms to Drive Growth and Expansion ...). In another case, **Mankind Pharma** in India worked with IBM Services to speed up its business analytics by 50x, unlocking new insights for efficiency gains (Life sciences industry solutions - IBM). While these are global examples outside the U.S., they reflect IBM's broad engagement in pharma's IT modernization worldwide – often IBM is the integrator that brings cloud, AI, and enterprise software together for a client. In the U.S., major pharmaceutical firms like **Merck, Johnson & Johnson, AstraZeneca, and Eli Lilly** have all worked with IBM at various points for projects ranging from AI pilots to infrastructure outsourcing. IBM's depth of experience in the domain (having a dedicated life sciences consulting practice) means it can often tailor solutions to pharma's unique requirements more effectively than smaller IT firms.

In summary, IBM's collaborations in pharma span early-stage discovery (AI, computational chemistry), clinical development (data analysis, trial management tools), manufacturing and supply chain (ERP, blockchain traceability), and commercial operations (analytics, CRM integrations). These case studies show IBM acting as an innovation partner and IT backbone for pharma companies, reinforcing its relevance in an industry that is adopting digital tech at an unprecedented pace.

Market Position vs. Competitors (AWS, Azure, Google)

IBM operates in a competitive landscape for pharma IT services, with cloud giants and tech firms all vying for market share in this lucrative industry. In the **cloud computing arena**, IBM Cloud's share in the healthcare and life sciences market is modest compared to leaders like AWS and Azure. As of 2020, Amazon Web Services held about **40%** of the healthcare cloud market, with Microsoft Azure at **18%** and Google Cloud around **12%**. IBM Cloud was estimated around **13%**, roughly on par with Google in that sector (The healthcare cloud race heats up - Becker's Hospital Review - Healthcare News & Analysis). These figures highlight that AWS and Azure have become the default choice for many pharma workloads – indeed, companies like Moderna and Johnson & Johnson run significant workloads on AWS, and Novartis and Merck have major collaborations with Microsoft Azure for data and AI projects. Google, through its Google Cloud Platform, has also gained traction, often emphasizing its strengths in data analytics and AI (e.g. many pharma researchers use Google's **AlphaFold** protein structure AI via cloud, and firms like Pfizer have engaged Google's AI teams for projects).

However, IBM differentiates itself by focusing on **integrated solutions and hybrid cloud**, rather than pure public cloud hosting. IBM often positions its offerings as *"enterprise-grade"* and tailored for industries: for instance, IBM Cloud has a **Healthcare/Life Sciences edition** with built-in compliance and security controls, whereas AWS/Azure require configuring those from a toolkit of services. This has made IBM Cloud appealing to organizations that require **an extra level of assurance** – for example, IBM Cloud's **Keep Your Own Key encryption** and **confidential computing** capabilities are not easily matched by competitors (Best HIPAA-Compliant Cloud Storage in 2025). A pharma company highly concerned about data sovereignty might choose IBM Cloud for specific sensitive workloads (say, genomic data analytics) while using AWS for less sensitive tasks.

Moreover, IBM's big competitive advantage is its **hybrid cloud ecosystem**. With Red Hat OpenShift, IBM enables pharma companies to run containerized workloads on any cloud (IBM, AWS, Azure, on-premises data centers, or at the edge) with a consistent platform. This is valuable in pharma where certain systems – due to IP or regulatory reasons – must remain on-premises, while other applications (like a web portal or a data lake) might benefit from public cloud scale. IBM's approach lets companies avoid cloud vendor lock-in and use multiple clouds securely. Indeed, IBM's strategy often involves *partnering* with the other cloud providers: IBM Consulting will help a pharma migrate to AWS or Azure if that's the client's choice, and then add

value through integration, security, and optimization services. IBM has even partnered with AWS to offer some of its software (like OpenPages, Maximo, etc.) as SaaS on AWS (IBM OpenPages), showing that IBM isn't purely competing on hosting, but rather on expertise and solutions.

When it comes to **AI and analytics**, IBM faces competition from not only cloud vendors but also specialized AI firms. Google's DeepMind (now Google DeepMind) has made headlines with its biological AI breakthroughs (AlphaFold's protein predictions), and companies like Microsoft have invested in bio-specific AI startups (e.g. Microsoft's partnership with biotech company Adaptive for AI-driven immunotherapy research). Yet, IBM can claim a rich legacy in AI for healthcare – Watson was a pioneer in many ways – and it continues to innovate with offerings like watsonx. IBM's emphasis is "AI for business" and "trustworthy AI," which appeals to pharma companies that must validate AI outputs and ensure explainability for regulators. IBM's new generative AI solutions will compete with offerings from Microsoft (which is incorporating OpenAI's models into Azure) and Google (with its Bard/LaMDA models and Vertex AI platform). A pharma IT team might evaluate, for example, Watsonx's chemistry models versus Google's tools or startups like Schrodinger and Insilico Medicine that specialize in drug discovery AI. IBM's value proposition here is often the **end-to-end support**: providing not just an AI model, but also the consulting services, integration with cloud/hardware, and even hardware accelerators (like IBM's AI-optimized **AC922 servers** or **Z systems**) required to deploy it effectively within the enterprise.

In **enterprise systems and consulting**, IBM competes with global firms like Accenture, Deloitte, and SAP in the pharma domain. IBM's consulting practice in life sciences offers strategy and implementation across R&D, supply chain, manufacturing, and marketing – similar in scope to Accenture's Life Sciences practice or Deloitte's. A unique angle for IBM is having its **IBM Research** division closely tied to its consulting projects; for instance, IBM can bring in a research scientist to advise a pharma client on quantum computing readiness (no other consulting firm could do that with in-house resources). Additionally, IBM's longstanding relationships and understanding of legacy systems (think of all the IBM mainframes and AS/400 systems that historically ran in pharma companies) make it a go-to partner for modernization projects. Competitors like AWS and Microsoft sometimes lack that historical footprint; they often partner with firms like IBM to actually execute deployments in complex environments.

To summarize IBM's market positioning: While IBM is no longer the dominant IT vendor across all areas, it has carved out a **strategic niche** in pharma by offering high-security cloud services, hybrid cloud flexibility, domain-specific AI innovations, and broad consulting expertise. Pharma companies often use a **multicloud** approach, and IBM typically plays a role in that mix – maybe not running the bulk of simple web services, but often powering the critical regulated systems or providing the integration glue and advanced research collaborations. IBM's focus on **trust, compliance, and partnership** distinguishes it from the pure tech approach of some competitors. This is evidenced by statements like IBM's commitment that "nearly 4,000 government and corporate entities in critical sectors (including healthcare) rely on IBM's hybrid cloud and Red Hat OpenShift to transform quickly, efficiently and securely" (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One). In an industry where a minor tech mistake

can have patient safety implications, IBM's cautious and client-tailored approach continues to hold appeal.

Conclusion

In the U.S. pharmaceutical industry, IBM today remains a relevant and multifaceted player. Its role has evolved from traditional IT backbone provider to an **innovation partner** offering AI prowess, secure cloud and infrastructure, and industry-specific services. IBM's contributions to pharmaceutical R&D – from the early Watson days of parsing scientific literature, to cutting-edge generative AI that designs new molecules – have helped blaze a trail for AI adoption in drug discovery. Its cloud and hybrid infrastructure solutions enable pharma companies to modernize IT while meeting stringent compliance and performance demands, often supporting systems that competitors' clouds find challenging. IBM's focus on **compliance, security, and trust** aligns naturally with pharma's regulatory environment, as seen in blockchain traceability pilots and its high-grade encryption offerings. Furthermore, IBM's numerous partnerships (with companies like Pfizer, Moderna, Boehringer Ingelheim) and joint initiatives (with Cleveland Clinic, FDA, VA) underline a collaborative approach – IBM is not just selling to pharma, but co-developing solutions to some of the industry's hardest problems.

That said, IBM operates in a very competitive context. Amazon, Microsoft, Google, and others are aggressively courting pharma with their cloud and AI solutions. IBM's share of the pharma tech market is smaller than it once was, prompting it to double-down on what it does best: hybrid cloud flexibility, deep industry expertise, and cutting-edge research. For IT professionals in pharma, IBM represents a **holistic option** – one that can integrate legacy systems with new cloud services, inject AI and even quantum computing into workflows, and do so with an eye on regulatory compliance and security at every step. In practice, many pharma companies will continue to use a mix of providers; IBM's strategy ensures it can remain a key part of that mix, often in the most mission-critical portions of the value chain.

As the pharmaceutical industry faces new challenges (like adapting to post-pandemic realities, personalized medicine, and faster drug development cycles), IBM's relevance will depend on its ability to keep delivering innovation. Current signs – such as IBM's work on quantum-enabled drug discovery and its launch of watsonx for life sciences – suggest IBM is committed to staying at the forefront. For IT teams, IBM offers not just technology, but a partnership grounded in decades of pharma experience. In the words of Cleveland Clinic's Chief Research Information Officer, *"We cannot afford to spend a decade or more going from a research idea in a lab to therapies on the market. Quantum offers a future to transform this pace."* (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One) This sense of urgency in pharma's digital transformation is exactly where IBM aims to be most relevant: accelerating the journey from lab to patient through trustworthy, powerful technology.

Sources: The information in this report is supported by citations from IBM case studies and press releases, pharmaceutical news outlets, and industry analyses, including IBM's collaboration announcements (Boehringer to use IBM's foundation model for antibody discovery) (Boehringer to use IBM's foundation model for antibody discovery), case studies like Pfizer's infrastructure overhaul (Pfizer - IBM) (Pfizer - IBM), reports on IBM's Watson Health evolution (Report: IBM is ending sales of Watson for Drug Discovery - MedCity News), details of IBM's quantum and AI partnerships with Cleveland Clinic and Moderna (Cleveland Clinic and IBM Begin Installation of IBM Quantum System One) (Moderna enlists IBM for quantum computing, AI training - Fierce Biotech), IBM Cloud security features (Best HIPAA-Compliant Cloud Storage in 2025), and market share data in healthcare cloud (The healthcare cloud race heats up - Becker's Hospital Review - Healthcare News & Analysis), among others. These demonstrate the breadth of IBM's engagement in the pharma sector and provide real-world context for IBM's current role.

DISCLAIMER

The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein.

Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document.

This document may contain content generated with the assistance of artificial intelligence technologies. Despite our quality control measures, AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it.

All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders.

IntuitionLabs.ai is an innovative AI consulting firm specializing in software, CRM, and Veeva solutions for the pharmaceutical industry. Founded in 2023 by Adrien Laurent and based in San Jose, California, we leverage artificial intelligence to enhance business processes and strategic decision-making for our clients.

This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.